Department of Biopharmaceutical Sciences

College of Pharmacy

Hayat Onyuksel, Ph.D.

Hayat Onyuksel, Ph.D.

Acting Assistant Head, Graduate Studies

Professor, Pharmaceutics and Bioengineering

Contact Information
833 South Wood Street
358 Pharm, MC 865
Chicago, IL 60612-7231
Office: (312) 996-2097
Fax: (312) 996-0098

Publications (2005-2009)
Phospholipid Micelles as Solubilizing Agents, Targeted Drug Carriers, and Sensitizers of Resistant Cells

Lim S.B, Banerjee A,Onyuksel H. Improvement of drug safety by the use of Lipid-based Nanocarriers. J.Control.Release 163: 34-45, 2012.

Cesur H, Rubinstein I, Pai A, Onyuksel H. Self-associated indisulam in phospholipid-based nanomicelles: a potential nanomedicine for cancer. Nanomedicine. 2009 Jun;5(2):178-83. Epub 2008 Dec 13. DOI

Onyuksel H, Jeon E, Rubinstein I. Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells. Cancer Lett. 2009 Feb 18;274(2):327-30. Epub 2008 Nov 20. DOI

Onyuksel H, Mohanty PS, Rubinstein I. VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: A novel targeted nanomedicine for breast cancer. Int J Pharm. 2009 Jan 5;365(1-2):157-61. Epub 2008 Aug 27. DOI

Rubinstein I, Soos I, Onyuksel H. Intracellular delivery of VIP-grafted sterically stabilized phospholipid mixed nanomicelles in human breast cancer cells. Chem Biol Interact. 2008 Jan 30;171(2):190-4. Epub 2007 Apr 6. DOI

Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine. 2005 Sep;1(3):193-212. DOI

Koo OM, Rubinstein I, Onyuksel H. Camptothecin in Sterically Stabilized Phospholipid Micelles: A Novel Nanomedicine. J. Nanomedicine. 2005 Sep;1:77-84. DOI